Latest Moclobemide Stories
RESEARCH TRIANGLE PARK, N.C., Jan. 6, 2011 /PRNewswire/ -- CeNeRx BioPharma, Inc., today reported that it has initiated a Phase II trial of its new formulation of TriRima(TM), the company's novel antidepressant in development as monotherapy for treatment resistant depression.
RESEARCH TRIANGLE PARK, N.C., Nov.
Monoamine oxidase-A inhibitor drug blocks buildup of toxic free radicals in animal hearts.
RESEARCH TRIANGLE PARK, N.C., Oct.
Regulatory News: Meda (STO:MEDAA) has reached an agreement with the Swiss pharma company Roche to acquire four of their well-established pharmaceutical products. The acquired products have strong brand names and the total sales level is 500 MSEK.
RESEARCH TRIANGLE PARK, N.C., July 22 /PRNewswire/ -- CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system, today announced plans to advance its lead candidate Tyrima(TM) into Phase II trials for the treatment of depression and anxiety.
- Having no light.